Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.61 USD | +1.07% | +6.73% | +17.99% |
05-07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
05-07 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.99% | 5.55B | |
+5.66% | 111B | |
+11.23% | 105B | |
-2.45% | 21.93B | |
-12.15% | 22.34B | |
-7.66% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics Insider Sold Shares Worth $800,262, According to a Recent SEC Filing